Haemonetics Corporation (HAE)
Debt-to-capital ratio
Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long-term debt | US$ in thousands | 797,564 | 856,849 | 748,662 | 751,381 | 754,102 | 756,826 | 759,552 | 763,141 | 559,441 | 633,118 | 698,043 | 767,345 | 690,592 | 292,721 | 297,016 | 296,893 | 305,513 | 309,738 | 313,984 | 318,144 |
Total stockholders’ equity | US$ in thousands | 959,959 | 943,319 | 893,660 | 864,616 | 817,997 | 775,979 | 729,009 | 770,423 | 749,424 | 730,775 | 698,549 | 677,080 | 731,670 | 719,152 | 667,923 | 608,569 | 587,109 | 574,580 | 583,754 | 590,966 |
Debt-to-capital ratio | 0.45 | 0.48 | 0.46 | 0.46 | 0.48 | 0.49 | 0.51 | 0.50 | 0.43 | 0.46 | 0.50 | 0.53 | 0.49 | 0.29 | 0.31 | 0.33 | 0.34 | 0.35 | 0.35 | 0.35 |
March 31, 2024 calculation
Debt-to-capital ratio = Long-term debt ÷ (Long-term debt + Total stockholders’ equity)
= $797,564K ÷ ($797,564K + $959,959K)
= 0.45
The debt-to-capital ratio of Haemonetics Corporation has fluctuated over the periods provided, ranging from a low of 0.29 to a high of 0.53. Generally, the ratio has shown a tendency to vary around the mid-0.4 range. This indicates that, on average, around 40-50% of the company's capital structure is financed by debt, with the remainder coming from equity.
It is worth noting that the ratio has experienced some volatility, with fluctuations potentially reflecting changes in the company's debt levels relative to its total capital. A lower ratio typically suggests a lower level of financial risk, as it indicates that the company relies less on debt financing. Conversely, a higher ratio may imply higher financial risk due to a larger proportion of debt in the capital structure.
Overall, it would be essential to monitor the trend in the debt-to-capital ratio over time to assess Haemonetics Corporation's evolving financial leverage and risk profile.
Peer comparison
Mar 31, 2024